Dr. Reddys Laboratories Ltd.

Dr. Reddys Laboratories is currently trading at Rs. 2748.50, up by 32.85 points or 1.21% from its previous closing of Rs. 2715.65 on the BSE.

The scrip opened at Rs. 2730.00 and has touched a high and low of Rs. 2758.00 and Rs. 2723.00 respectively. So far 11139 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 3689.00 on 20-Jul-2016 and a 52 week low of Rs. 2382.05 on 29-May-2017.

Last one week high and low of the scrip stood at Rs. 2758.00 and Rs. 2685.00 respectively. The current market cap of the company is Rs. 45650.44 crore.

The promoters holding in the company stood at 26.79 %, while Institutions and Non-Institutions held 42.95% and 13.87% respectively.

Dr. Reddy’s Laboratories has launched Vozet Tablets in Indian market. The drug is indicated for the treatment of allergic Rhinitis and chronic Urticaria. Vozet Tablets contain Levocetirizine 5 mg, and are available in a strip size of 10 tablets.

The anti-histamine market in India had sales of Rs 1,038 crore MAT for the most recent twelve months ended in March 2017, according to IMS data. The pharma major will further strengthen its anti-allergy portfolio with the addition of Vozet.

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.